雙磷酸鹽治療攝護腺癌骨轉移病人-新光醫院的經驗
仇光宇1,3、蔡德甫1,3、黃一勝1,2,3、莊光達1,3、葉忠信1,3、鄭以弘1、林宜佳1.3
1新光醫院 外科部 泌尿科；2台北醫學大學醫學院; 3輔仁大學醫學院
Biphosphonate therapy in the patient of bony metastatic prostate cancer-the experience of one institute
Kuang-Yu Chou1,3, Te-Fu Tsai1,3, Thomas I-Sheng Hwang1,2,3, Guang –Dar Juang1,3, Chung-Hsin Yeh1,3, Yi-Hong Cheng, Yi-Chia Lin1,3
1Department of Urology, Shin Kong Wu Ho-Su Memorial Hospital,
2 Department of Urology, Taipei Medical University,
3Division of Urology, School of Medicine, Fu-Jen Catholic University
Purpose: Bisphosphonates were used as to prevent loss of bone mass, treat osteoporosis, and prevent some metastatic cancer induced skeletal-related events. In the patients of bony metastatic disease of multiple myeloma, breast cancer, and prostate cancer, the biphosphonate therapy is indicated for reduce the bone pain and fracture. We report the experiences in a single institute.
Materials and Methods: Retrospectively reviewed the medical records of the patient started from 2011 till present. The adverse events of the patient during the period such as skeletal fracture and osteonecrosis of the jaw were recorded. All the patients had been evaluated and treated by dentist in our hospital. There were two kinds of bisphosphonates available in our hospital.
Results: Totally 25 patients of prostate cancer fulfill the indication were included in the study periods. Seven patients died of disease. There was no skeletal fracture recorded in this period. There were 3 (12 %) patients developed the complication of osteonecrosis of the jaw (ONJ). Thirteen patients started with zoledronic acid, and the other twelve patients started withdenosumab.
Conclusions: The biphosphonates therapy can prevent skeletal related event in bony metastatic patients of prostate cancer. About 12% developed ONJ in our series. The further detailed data will be reported and literature will be reviewed.